<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2846">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124119</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2021-0917</org_study_id>
    <secondary_id>UG1DA020024</secondary_id>
    <nct_id>NCT05124119</nct_id>
  </id_info>
  <brief_title>Strategies to Enhance Recruitment and Retention of Black Individuals Into Clinical Trials for Substance Use Disorders</brief_title>
  <acronym>I-DREM</acronym>
  <official_title>Innovative Development of Research Engagement Manual (I-DREM): Strategies to Enhance Recruitment and Retention of African American/Black Individuals in Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this research project will be to obtain feedback from consumers to help&#xD;
      develop a manual called I-DREM (Innovative Development of Research Engagement Manual). The&#xD;
      researchers hope to learn information from the consented participants to help map out&#xD;
      solutions to improve recruitment of African American/Black individuals into Substance Abuse&#xD;
      Disorder (SUD) clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Black individuals represent 12% of the U.S. population. Approximately 3% participate in&#xD;
      various clinical trials in the entire country. Black individuals are disproportionately&#xD;
      affected by substance use and have higher rates of associated mortality, suggesting the need&#xD;
      for action to address this racial disparity in health outcomes. Under-representation of&#xD;
      ethnic minorities in clinical trials has significant scientific implications and ultimately&#xD;
      compromises generalizability of research findings and further exacerbates existing racial&#xD;
      health disparities.&#xD;
&#xD;
      Although incremental progress has occurred since the establishment of the National Institutes&#xD;
      of Health (NIH) Revitalization Act, barriers that influence participation of the African&#xD;
      American and ethnic minority populations in research continue to exist. The NIH has&#xD;
      acknowledged the need for increased enrollment of ethnic minorities in research, yet minority&#xD;
      enrollment into clinical and translational research remains low. There are no concrete&#xD;
      developments (e.g., protocols, toolbox) to aid clinical researchers' effort to enhance&#xD;
      recruitment and retention to date in substance using populations despite the detrimental&#xD;
      disproportionate effects of substance use observed in the African American and or Black&#xD;
      populations. This suggests the importance of initiating more innovative ways of retainment,&#xD;
      recruitment, and education of ethnic minorities about Substance Use Disorders (SUDs).&#xD;
&#xD;
      Specifically, almost 1 million Americans, an estimated 977,000, met criteria for cocaine use&#xD;
      disorder in 2018. The rate of overdose deaths attributed to cocaine increased by an average&#xD;
      of 27% each year from 2012 to 2018, reaching a rate of 4.5 deaths per 100,000 standard&#xD;
      population in 2018. This increase is a tripling in deaths from the year 2012 to 2018 and&#xD;
      appears to be continuing to increase. The rate of death is highest among non-Hispanic Blacks&#xD;
      at a rate of 8.3 per 100,000 population, which is nearly double the rate of death attributed&#xD;
      to cocaine among non-Hispanic Whites. This differential death rate is seen despite similar&#xD;
      rates of cocaine use among Blacks and Whites is 1.8 % versus 2.1%, respectively in 2018,&#xD;
      suggesting the need for action to address this racial disparity in health outcomes.&#xD;
&#xD;
      Significance: Nearly 40% of Americans belong to a racial or ethnic minority group. However,&#xD;
      participants in clinical trials for new pharmacotherapies skew heavily Caucasian. In the area&#xD;
      of substance use disorders, Blacks are also disproportionally affected and have higher rates&#xD;
      of associated mortality. One study using data from multiple Clinical Trials Network trials&#xD;
      showed higher rates of combined opiate and stimulant use among Black compared to White&#xD;
      adults. The rate of death is also highest among Black participants using cocaine at a rate of&#xD;
      8.3 per 100,000 population, which is nearly double the rate of death attributed to cocaine&#xD;
      among non-Hispanic Whites. This differential death rate is seen despite similar rates of&#xD;
      cocaine use among Blacks and Whites suggests the need for action to address this racial&#xD;
      disparity in health outcomes. Under-representation of ethnic minorities in clinical trials&#xD;
      has significant scientific implications and ultimately compromises generalizability of&#xD;
      research findings and further exacerbates existing racial health disparities.&#xD;
&#xD;
      Rationale: While significant attention has been devoted to identifying barriers to inclusion,&#xD;
      the current proposal seeks to redirect efforts away from documenting barriers and instead&#xD;
      towards improved recruitment and retention of Black/African American (AA) individuals into&#xD;
      Randomized Clinical Trials (RCTs). This will be achieved by developing a comprehensive and&#xD;
      innovative manual that maps out concrete strategies for both increased recruitment and&#xD;
      retention in RCTs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in knowledge Acquisition Scores</measure>
    <time_frame>Baseline Day 1-15 (pre-focus group), Post focus group (Day 15-30) [Approximated time frames]</time_frame>
    <description>The &quot;Research Knowledge Questionnaire&quot; measures participants' knowledge acquisition.&#xD;
Possible score ranges from 0 - 100 i.e., 0-24 referring to low knowledge, 25-49 referring to below average, 51-74 referring to good scores, and 75-100 higher scores indicating excellent and higher knowledge acquisition (research knowledge).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Focus Group One</arm_group_label>
    <description>Participants in Focus Group 1 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Focus Group Two</arm_group_label>
    <description>Participants in Focus Group 2 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        African American persons, male and female, 18 years to 90 years that have a history of&#xD;
        substance abuse disorder and have competed rehabilitation and not actively using illicit&#xD;
        drugs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Self-identified as Black American or of African American heritage&#xD;
&#xD;
          -  Is using and looking to stop or reduce their cocaine use and or other illicit&#xD;
             substance use&#xD;
&#xD;
          -  Has access to device for virtual meetings&#xD;
&#xD;
          -  Able to provide informed consent and complete verbal study assessments in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -All that does not meet the inclusion criteria from (i) to (v) above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Madhukar Trivedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hoa Vo, PhD</last_name>
    <phone>202-956-8387</phone>
    <email>hoa.vo@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geoffrey Obel, MPH</last_name>
    <email>geoffrey.obel@utsouthwestern.edu</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Magruder KM, Bichun Ouyang, Miller S, Tilley BC. Retention of under-represented minorities in drug abuse treatment studies. Clin Trials. 2009 Jun;6(3):252-60. doi: 10.1177/1740774509105224.</citation>
    <PMID>19528134</PMID>
  </results_reference>
  <results_reference>
    <citation>Byrne MM, Tannenbaum SL, Gl√ºck S, Hurley J, Antoni M. Participation in cancer clinical trials: why are patients not participating? Med Decis Making. 2014 Jan;34(1):116-26. doi: 10.1177/0272989X13497264. Epub 2013 Jul 29.</citation>
    <PMID>23897588</PMID>
  </results_reference>
  <results_reference>
    <citation>Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004 Jun 9;291(22):2720-6.</citation>
    <PMID>15187053</PMID>
  </results_reference>
  <results_reference>
    <citation>Hedegaard H, Spencer MR, Garnett MF. Increase in Drug Overdose Deaths Involving Cocaine: United States, 2009-2018. NCHS Data Brief. 2020 Oct;(384):1-8.</citation>
    <PMID>33054918</PMID>
  </results_reference>
  <results_reference>
    <citation>Hayen A, Wanigasekera V, Faull OK, Campbell SF, Garry PS, Raby SJM, Robertson J, Webster R, Wise RG, Herigstad M, Pattinson KTS. Opioid suppression of conditioned anticipatory brain responses to breathlessness. Neuroimage. 2017 Apr 15;150:383-394. doi: 10.1016/j.neuroimage.2017.01.005. Epub 2017 Jan 3.</citation>
    <PMID>28062251</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Madhukar H. Trivedi, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

